|
An updated analysis of ICOGEN to demonstrate utility of a blood-based proteomic test to predict outcomes in EGFR TKI treated patients. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Biodesix |
| |
|
|
Stock and Other Ownership Interests - Biodesix |
| |
|
Employment - Biodesix; Personalized Diagnostics |
Leadership - Personalized Diagnostics |
Stock and Other Ownership Interests - Personalized Diagnostics |
Consulting or Advisory Role - Biodesix |
| |
|
No Relationships to Disclose |
| |
|
|
|
Stock and Other Ownership Interests - Biodesix; miRagen |
Research Funding - Biodesix |
Patents, Royalties, Other Intellectual Property - Biodesix; Roche |
Travel, Accommodations, Expenses - Biodesix; miRagen |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |